Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook




 

Gene mutation for liver disease corrected in human stem cells

17 October 2011

By Luciana Strait

Appeared in BioNews 629

Genetics and stem cell research have been combined for the first time to correct a genetic mutation associated with liver disease. This new approach could lead to people with a genetic disease being treated with their own cells.

The research 'represents a first step towards personalised cell therapy for genetic disorders of the liver', said Dr Ludovic Vallier of the University of Cambridge's Anne McLaren Laboratory for Regenerative Medicine, one of researchers involved in the study.

The study, published in Nature, used cells containing the genetic mutation linked to liver disease taken from a patient to produce iPS cells. These stem cells can differentiate into other types of cells, such as liver cells, but cannot instantly be used in humans as they contain the corrupted genetic code responsible for the disease.

To correct the mutation, the researchers used an engineered molecule which removed the faulty sequence in the gene, replacing it with a functioning sequence. The stem cells were then grown into liver cells and tested both in the lab and in mice, where they 'functioned beautifully with normal secretion and function', according to Professor David Lomas, deputy director of the Cambridge Institute for Medical Research, University of Cambridge, who was involved in the study.

The researchers examined a gene which protects against inflammation in the liver by producing a certain protein called α1-antitrypsin. In people with a mutation in the gene the protein becomes trapped in the liver which can lead to cirrhosis and eventually liver failure. When the corrected cells were transplanted into mouse livers, the researchers found that the cells had integrated and begun to produce and release protein appropriately.

The authors suggest this approach is significantly more efficient than other gene-targeting technologies currently available. 'Most gene therapy is not correcting the gene, it's introducing a new copy of the gene', said Robin Ali, Professor of Human Molecular Genetics at University College London, who was not involved in the study. 'What's exciting is that this corrects', he added. Dr Vallier explained further: 'The genetic correction doesn't increase the number of genetic anomalies that you can find in iPS cells'.

The research is still at a very early stage, however, and the study was aimed simply to develop the technique. According to the BBC, Professor Lomas said the technique was 'ridiculously hard', but acknowledged 'the potential is enormous'. 'The key thing is safety', he said, and further research and clinical trials are needed before any treatments can be developed.

SOURCES & REFERENCES
BBC | 13 October 2011
 
Telegraph | 12 October 2011
 
Nature | 12 October 2011
 
Wellcome Trust press release | 13 October 2011
 
Guardian | 12 October 2011
 
NHS Choices Behind the Headline | 13 October 2011
 
Nature | 12 October 2011
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

03 March 2014 - by Dr Naqash Raja 
'Mini livers' grown from mouse stem cells could reduce the need for laboratory testing on animals, thanks to research from the University of Cambridge....
06 February 2012 - by Dr Linda Wijlaars 
The best treatment for tuberculosis (TB) could depend on which version of a particular gene the patient has. Researchers from the UK, US and Vietnam combined studies in zebrafish with clinical work to identify a gene that controls the inflammatory response in TB. It is one of the first applications of personalised medicine outside of cancer medicine...

10 October 2011 - by Dr Louisa Petchey 
US scientists have for the first time created 'personalised' human embryonic stem cells (hESCs) using a form of cloning. The result is a significant milestone on the route to using stem cell-based therapies but the researchers stress more work is to be done as genetic errors in the cells means they are not yet suitable for therapeutic use....
30 August 2011 - by Rosemary Paxman 
Over a dozen children with 'boy in bubble' syndrome are alive and well, with functioning immune systems, nine years after undergoing gene therapy to correct their disorder, researchers report....
18 July 2011 - by Dr Rebecca Robey 
Canadian scientists have identified a master stem cell that is capable of becoming any of the different types of cell found in blood. The discovery offers hope of alternative treatments for people who would normally require bone marrow transplants to replenish their blood supply, for example those with cancer or blood disorders...
21 March 2011 - by Julianna Photopoulos 
UK scientists have found 15 new genetic regions that may affect a person's risk of developing primary biliary cirrhosis, a chronic form of liver disease...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation